Advertisement

Topics

Search Results for "Buprenorphine Lc Ms Ms Method"

18:50 EST 7th February 2016 | BioPortfolio

Matching Channels

DNA-FISH Probes

Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid...

Spirometry Test

The gold standard in lung testing In the same way that blood pressure measurements provide a simple yet effective screening method for cardiovascular disease, spirometry tests can help to unmask t...

Herpes simplex virus HSV 1 HSV 2 HHV 1 HHV 2

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family that infect humans. HSV-1 and HSV-2 cause the vira...

Breast Implants - Augmentation

Breast implants are medical devices that are used to augment breast size or to reconstruct the breast following mastectomy or to correct a congenital abnormality. Breast implants consist of a silico...

ImuXen

ImuXen® is a liposomal technology platform designed to improve the delivery and effectiveness of DNA, protein and polysaccharide vaccines. Proof of concept preclinical studies with a number of...

Matching News

FDA Approves Zubsolv for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence

Uppsala, Sweden – August 11, 2015 - Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved Zubsolv (buprenorphine/naloxone CIII sublingual tablet) for inductio...

Probuphine's FDA Panel Return: Efficacy Concerns Despite Narrowed Population

Have Braeburn and Titan demonstrated their subdermal buprenorphine implant is non-inferior to buprenorphine sublingual tablets in stable opioid-dependent patients?

Orexo: U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence

UPPSALA, Sweden–(BUSINESS WIRE)–Regulatory News: Orexo (STO:ORX) Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/...

Opioid Switch to Buccal Buprenorphine May Limit Withdrawal

Patients taking morphine or oxycodone for pain can be safely switched to buccal buprenorphine without tapering and without causing significant withdrawal, a new study suggests. Medscape Medical New...

FDA Okays Buccal Buprenorphine (Belbuca) in Chronic Pain

Endo Pharmaceuticals announces FDA approval for buprenorphine buccal film for the treatment of chronic pain. FDA Approvals

FDA Approves Belbuca (Buprenorphine) Buccal Film for Chronic Pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Belbuca (...

Orexo: U.S. FDA Approves ZUBSOLV for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence

Regulatory News: Orexo (STO:ORX) Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) for inductio...

FDA Grants Fast Track Designation for Long-acting Buprenorphine Injections to Treat Opioid Addiction

​Braeburn Pharmaceuticals and Camurus announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the CAM2038 weekly and monthly buprenorphine subcutaneous in...

Matching PubMed Articles

Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Neonatal abstinence syndrome (NAS)-a clinical entity of infants from in utero exposure to psychoactive xenobiotic and buprenorphine-has been successfully used to treat NAS. However, nothing is known a...

Buprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment Organizations.

Buprenorphine, a medication for treating opioid dependence, is underutilized in specialty addiction treatment organizations. Only physicians who have obtained a buprenorphine prescribing license or "w...

Optimizing Psychosocial Support During Office-Based Buprenorphine Treatment in Primary Care: Patients' Experiences and Preferences.

Buprenorphine maintenance treatment is effective and has been successfully integrated into HIV and primary care settings. However, one key barrier to providers prescribing buprenorphine is their perce...

A Retrospective Evaluation of Inpatient Transfer from High-Dose Methadone to Buprenorphine Substitution Therapy.

The product license of buprenorphine/naloxone for opioid substitution therapy indicates reducing methadone concentrations to 30mg or less per day for a minimum of 1week before transferring patients to...

Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program.

Use of buprenorphine - an effective treatment for opioid use disorders (OUDs) - has increased rapidly in recent years and is often financed by Medicaid. We investigated predictors of buprenorphine tre...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement